Given the collapse of all the inhaled insulin collaborations, many observers are skeptical that the Novo/Emisphere collaboration to create an oral version of Novo's liraglutide GLP-1 -- the drug-delivery company's biggest deal ever -- will work out any better. GLP-1, however, doesn't have all the baggage of insulin therapy, so there is in fact better logic for an oral pill's success. Still, if the program creates merely an oral version of once-a-day liraglutide, with no clinical advantages over its GLP-1 competitors, it will die just as certainly as did inhaled insulin.
There’s got to be some reward for just not giving up.
Take Michael Goldberg, the former CEO of Emisphere Technologies Inc. Following 10 years of development, Emisphere’s oral insulin rather...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
